TLR4 and myelodysplastic syndrome: Corroborating this evidence, ex vivo treatment with AZA was able to reduce both mH2A1.1 and TLR4 protein levels also in MSCs from MDS patients (n = 4) (p < 0.0001 and p < 0.01 compared to control cells; Fig. 6D, E).